Supernus Pharmaceuticals Inc (SUPN)

Working capital turnover

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	US$ in thousands	607,521	673,056	560,079	500,962	392,755
Total current assets	US$ in thousands	493,113	734,151	601,590	630,417	472,644
Total current liabilities	US$ in thousands	290,196	687,958	315,379	245,108	160,587
Working capital turnover		2.99	14.57	1.96	1.30	1.26

December 31, 2023 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $607,521K ÷ ($493,113K – $290,196K)
= 2.99

The working capital turnover for Supernus Pharmaceuticals Inc has fluctuated over the past five years, indicating varying efficiency in managing its working capital. In 2023, the working capital turnover was 2.99, a significant decline from the exceptionally high value of 14.44 in 2022. This suggests that the company was able to convert its working capital into revenue at a slower rate in 2023 compared to the previous year.

Furthermore, the working capital turnover of 2.03 in 2021 indicates an improvement from 1.35 in 2020 and 1.26 in 2019. This could suggest enhanced efficiency in utilizing its working capital to generate revenue in 2021 compared to the previous years.

Overall, the trend in Supernus Pharmaceuticals Inc's working capital turnover indicates fluctuations in its operational efficiency and the management of its working capital over the years, with some years showing better performance than others. It is essential for the company to analyze the factors contributing to these fluctuations and take appropriate measures to maintain and improve its working capital turnover in the future.